NCT07321249 is a clinical trial in Obesity, sponsored by Alaa Mohamed Naguib Ashry.

Who is sponsoring NCT07321249?

NCT07321249 is sponsored by Alaa Mohamed Naguib Ashry.

Is NCT07321249 still recruiting?

NCT07321249 is currently not yet recruiting. Last updated 9 January 2026.

Last reviewed 2026-01-09 · How we verify

NCT07321249

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Is There an Association Between Smartsphone Addiction and Obesity in Young Adults?

Not yet recruiting Last updated 9 January 2026

What this trial tests

trial in Obesity in 212 participants. Not yet recruiting.

Timeline

20 December 2025

Primary endpoint
20 February 2026

20 March 2026

Quick facts

Lead sponsor	Alaa Mohamed Naguib Ashry
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	212
Start date	20 December 2025
Primary completion	20 February 2026
Estimated completion	20 March 2026

Conditions studied

Obesity — all drugs for Obesity →

Sponsor

Alaa Mohamed Naguib Ashry

Who can join

Adults 18 to 25, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

BACKGROUND: smartphone dependence causes adverse effects on one's lifestyle such as dietary habits and daily routines, resulting in overweight or obesity. Additionally, academic stress also contributes to addictive behaviors, such as smartphone addiction. Research shows that problematic smartphone use is significantly associated with loneliness, low self-esteem, and depression. Poor mental health is also proven to be a risk factor for obesity in young adults.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07321249 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alaa Mohamed Naguib Ashry
Last refreshed: 9 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07321249.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing